Economic Dimensions of Personalized and Precision Medicine
392 pages
|
91 line drawings, 67 tables
|
6 x 9
|
© 2019
- Contents
Table of Contents
Contents
Acknowledgment
Introduction
Ernst R. Berndt, Dana Goldman, and John Rowe
1. The Economic Value and Pricing of Personalized Medicine
Tomas J. Philipson
2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS
Manuel Hermosilla and Jorge Lemus
3. The Value of Pharmacogenomic Information
John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson
4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory
Ernst R. Berndt and Mark R. Trusheim
5. Characterizing the Drug Development Pipeline for Precision Medicines
Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern
6. Cost Sharing in Insurance Coverage for Precision Medicine
Mark V. Pauly
7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments
Kristopher J. Hult
8. Physicians’ Financial Incentives to Personalize Medicine
David H. Howard, Jason Hockenberry, and Guy David
9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan
Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang
10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger
Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright
11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
Philippe Gorry and Diego Useche
Introduction
Ernst R. Berndt, Dana Goldman, and John Rowe
1. The Economic Value and Pricing of Personalized Medicine
Tomas J. Philipson
2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS
Manuel Hermosilla and Jorge Lemus
3. The Value of Pharmacogenomic Information
John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson
4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory
Ernst R. Berndt and Mark R. Trusheim
5. Characterizing the Drug Development Pipeline for Precision Medicines
Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern
6. Cost Sharing in Insurance Coverage for Precision Medicine
Mark V. Pauly
7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments
Kristopher J. Hult
8. Physicians’ Financial Incentives to Personalize Medicine
David H. Howard, Jason Hockenberry, and Guy David
9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan
Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang
10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger
Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright
11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
Philippe Gorry and Diego Useche
For more information, or to order this book, please visit https://press.uchicago.edu
Google preview here
Economics and Business: Health Economics
You may purchase this title at these fine bookstores. Outside the USA, see our international sales information.
